ResMed (RMD) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $253.06 +2.79%
Revenue Growth %: +6.9%
Financial Fact:
Income taxes (note 13): 16.82M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +6.9%
Financial Fact:
Income taxes (note 13): 16.82M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $0.73, $0.03 better than the analyst estimate of $0.70. Revenue for the quarter came in at $530.4 million versus the consensus estimate of $515.94 million.
"We had a strong quarter with 18 percent constant currency revenue growth led by solid growth in our Brightree software offerings and global device sales," said Mick Farrell, ResMed's CEO
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- FVCBankcorp, Inc. (FVCB) Misses Q3 EPS by 2c
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
